The identified LGALS1-associated compounds (such as zoledronate and pazopanib) may provide a basis for tailored treatment strategies in GBM, particularly for patients with tumors characterized by an immunosuppressive, M2-macrophage-rich microenvironment. Here, LGALS1 is linked to glioblastoma.